Takeda Pharmaceutical Company Limited
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
7882.7% vs price
Base Case (Median)
15240.5% vs price
Bull Case (75th pct.)
24463.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $6279.39 | 36030.0% | High (40%) |
| PE Comparable | $1258.04 | 7138.4% | Medium (25%) |
| Graham Number | $1775.49 | 10115.7% | Medium (40%) |
| EV/EBITDA | $4506.60 | 25829.8% | Medium (20%) |
| EV/FCF | $3556.87 | 20365.3% | Medium (20%) |
| Earnings Power Value | $578.40 | 3227.9% | Medium (50%) |
Based on 6 out of 8 methods, TAK appears undervalued at the current price of $17.38. The base case fair value of $2666.18 implies 15240.5% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.